AAIPharma Services, Cambridge Major Laboratories Name Executive VP - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

AAIPharma Services, Cambridge Major Laboratories Name Executive VP

AAIPharma Services, a provider of pharmaceutical analytical testing, product development, and manufacturing services, and Cambridge Major Laboratories, a provider of pharmaceutical API development and manufacturing, have appointed Jeff Yuen as executive vice-president, global quality. Yuen has served as food and drug investigator at the State of California’s, Department of Health Services and was a Commander in the US Public Health Service at FDA. He also was GMP auditor, GMP advisor or FDA advisory committee member at National Nutritional Foods Association, Dietary Supplement, and BIOCOM. After leaving the FDA, he led an independent firm focused on FDA compliance and regulatory consulting for the dietary supplement, pharmaceutical, and biotechnology industries.

Source:AAIPharma Services


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here